Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Hyperglycaemia is associated with impaired pulsatile insulin secretion: effect of basal insulin therapy.

Meier JJ, Pennartz C, Schenker N, Menge BA, Schmidt WE, Heise T, Kapitza C, Veldhuis JD.

Diabetes Obes Metab. 2013 Mar;15(3):258-63. doi: 10.1111/dom.12022.

PMID:
23039360
2.

Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes.

Pennartz C, Schenker N, Menge BA, Schmidt WE, Nauck MA, Meier JJ.

Diabetes Care. 2011 Sep;34(9):2048-53. doi: 10.2337/dc11-0471. Epub 2011 Jul 20.

3.

Beta-cell function and mass in type 2 diabetes.

Larsen MO.

Dan Med Bull. 2009 Aug;56(3):153-64.

PMID:
19728971
4.

Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.

Giugliano D, Ceriello A, Razzoli E, Esposito K.

Clin Drug Investig. 2008;28(4):199-210. Review.

PMID:
18345710
6.

Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.

Shapiro ET, Van Cauter E, Tillil H, Given BD, Hirsch L, Beebe C, Rubenstein AH, Polonsky KS.

J Clin Endocrinol Metab. 1989 Sep;69(3):571-6.

PMID:
2503533
7.

Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

Diabetes. 2001 Aug;50(8):1778-84.

8.

Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM.

McMahon M, Marsh HM, Rizza RA.

Diabetes. 1989 Mar;38(3):291-303.

PMID:
2492963
9.

Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes.

Menge BA, Grüber L, Jørgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, Holst JJ, Meier JJ.

Diabetes. 2011 Aug;60(8):2160-8. doi: 10.2337/db11-0251. Epub 2011 Jun 15.

11.

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75. doi: 10.1111/j.1464-5491.2008.02579.x.

PMID:
19046215
12.

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.

Henry RR, Smith SR, Schwartz SL, Mudaliar SR, Deacon CF, Holst JJ, Duan RY, Chen RS, List JF.

Diabetes Obes Metab. 2011 Sep;13(9):850-8. doi: 10.1111/j.1463-1326.2011.01417.x.

PMID:
21554520
13.

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD.

Diabetes Care. 1997 Oct;20(10):1539-42.

PMID:
9314631
15.

Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.

Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M.

Metabolism. 2005 Sep;54(9):1168-73.

PMID:
16125528
16.

TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.

Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, Takeuchi K.

J Pharmacol Exp Ther. 2011 Oct;339(1):228-37. doi: 10.1124/jpet.111.183772. Epub 2011 Jul 13.

17.

Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism.

Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA.

Diabetes Care. 2009 May;32(5):866-72. doi: 10.2337/dc08-1826. Epub 2009 Feb 5.

18.

Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

Diabetes Care. 2002 Dec;25(12):2147-52.

PMID:
12453952
19.

Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes.

Beisswenger PJ, Brown WV, Ceriello A, Le NA, Goldberg RB, Cooke JP, Robbins DC, Sarwat S, Yuan H, Jones CA, Tan MH; IOOI Study Investigators.

Diabet Med. 2011 Sep;28(9):1088-95. doi: 10.1111/j.1464-5491.2011.03324.x.

20.

Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes.

Gredal C, Rosenfalck AM, Dejgaard A, Hilsted J.

Scand J Clin Lab Invest. 2007;67(3):327-36.

PMID:
17454847
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk